Try

Oric Pharmaceuticals, Inc.

ORICUnited States

25 filed reports · 240 financial concepts · 0 earnings calls · 0 media appearances

Filed reports

25 reports · Mar 2020 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR191,976Mar 2020 to Jun 2026
Annual · 10-KSEC EDGAR61,753Dec 2020 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 3, 2026220Open
FY2026 Q110-QMar 31, 2026May 4, 2026116Open
FY202510-KDec 31, 2025Feb 23, 2026381Open
FY2025 Q310-QSep 30, 2025Nov 13, 2025135Open
FY2025 Q210-QJun 30, 2025Aug 12, 202576Open
FY202410-KDec 31, 2024Feb 18, 2025259Open
FY2024 Q310-QSep 30, 2024Nov 12, 202498Open
FY2024 Q210-QJun 30, 2024Aug 12, 202480Open
FY2024 Q110-QMar 31, 2024May 6, 2024115Open
FY202310-KDec 31, 2023Mar 11, 2024265Open
FY2023 Q310-QSep 30, 2023Nov 6, 2023110Open
FY2023 Q210-QJun 30, 2023Aug 10, 202377Open

Financial data

240 concepts · 3,729 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial239 concepts · 3,718 facts · Dec 2018 to Jul 2026

  • Cash cash equivalents restricted cash and restricted cash equivalents39 · Dec 2018 to Jun 2026
  • Stockholders equity (US GAAP)39 · Dec 2018 to Jun 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value38 · Dec 2018 to Jun 2026
  • Allocated share based compensation expense38 · Dec 2018 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect38 · Dec 2018 to Jun 2026
  • Depreciation38 · Dec 2018 to Jun 2026
  • General and administrative expense (US GAAP)38 · Dec 2018 to Jun 2026
  • Increase decrease in accounts payable and accrued liabilities38 · Dec 2018 to Jun 2026
  • Increase decrease in prepaid deferred expense and other assets38 · Dec 2018 to Jun 2026
  • Net cash provided by used in financing activities38 · Dec 2018 to Jun 2026
  • Net cash provided by used in investing activities38 · Dec 2018 to Jun 2026
  • Net cash provided by used in operating activities38 · Dec 2018 to Jun 2026
  • Net income loss38 · Dec 2018 to Jun 2026
  • Nonoperating income expense38 · Dec 2018 to Jun 2026
  • Operating expenses (US GAAP)38 · Dec 2018 to Jun 2026
  • Operating income loss38 · Dec 2018 to Jun 2026
  • Payments to acquire property plant and equipment38 · Dec 2018 to Jun 2026
  • Proceeds from stock options exercised38 · Dec 2018 to Jun 2026
  • Profit loss38 · Dec 2018 to Jun 2026
  • Share based compensation38 · Dec 2018 to Jun 2026
  • Comprehensive income net of tax36 · Dec 2018 to Jun 2026
  • Research and development expense excluding acquired in process cost36 · Dec 2018 to Jun 2026
  • Cash and cash equivalents at carrying value34 · Dec 2019 to Jun 2026
  • Accounts payable current33 · Dec 2019 to Jun 2026

Geography1 concepts · 11 facts · Dec 2018 to Dec 2020

  • Operating leases rent expense net11 · Dec 2018 to Dec 2020

Segments

11 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement geographical1 member · 11 facts

  • South San Francisco And San Diego Locations11 · Dec 2018 to Dec 2020

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Oric Pharmaceuticals, Inc. (ORIC) data · FactIQ